Literature DB >> 8215724

Plasma lipoprotein levels as predictors of cardiovascular death in women.

K M Bass1, C J Newschaffer, M J Klag, T L Bush.   

Abstract

BACKGROUND: The association of lipoprotein levels with cardiovascular disease (CVD) is less well understood in women than in men. To better characterize any relationships, associations between CVD death and total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol and triglyceride levels in women were explored using data from female participants in the Lipid Research Clinics' Follow-up Study.
METHODS: Using a sample of 1405 women aged 50 to 69 years from the Lipid Research Clinics' Follow-up Study, age-adjusted CVD death rates and summary relative risk (RR) estimates by categories of lipid and lipoprotein levels were calculated. Multivariate analysis was performed to provide RR estimates adjusted for other CVD risk factors.
RESULTS: Average follow-up was 14 years. High-density lipoprotein and triglyceride levels were strong predictors of CVD death in age-adjusted and multivariate analyses. Low-density lipoprotein and total cholesterol levels were poorer predictors of CVD mortality. After adjustment for other CVD risk factors, HDL levels less than 1.30 mmol/L (50 mg/dL) were strongly associated with cardiovascular mortality (RR = 1.74; 95% confidence interval [CI], 1.10 to 2.75). Triglyceride levels were associated with increased CVD mortality at levels of 2.25 to 4.49 mmol/L (200 to 399 mg/dL) (RR = 1.65; 95% CI, 0.99 to 2.77) and 4.50 mmol/L (400 mg/dL) or greater (RR = 3.44; 95% CI, 1.65 to 7.20). At total cholesterol levels of 5.20 mmol/L (200 mg/dL) or greater and at all levels of LDL and triglycerides, women with HDL levels of less than 1.30 mmol/L (< 50 mg/dL) had CVD death rates that were higher than those of women with HDL levels of 1.30 mmol/L (50 mg/dL) or greater.
CONCLUSIONS: High-density lipoprotein and triglyceride levels are independent lipid predictors of CVD death in women. Cholesterol screening guidelines should be re-evaluated to reflect the importance of HDL and triglyceride levels in determining CVD risk in women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8215724

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  46 in total

1.  Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study.

Authors:  Samia Mora; Julie E Buring; Paul M Ridker; Yadong Cui
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

Review 2.  Evidence-based management of dyslipidemias in women.

Authors:  John C LaRosa
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 3.  Cardiovascular disease and primary ovarian insufficiency.

Authors:  Melissa Wellons
Journal:  Semin Reprod Med       Date:  2011-10-03       Impact factor: 1.303

4.  Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause.

Authors:  Samar R El Khoudary; Patrick M Hutchins; Karen A Matthews; Maria M Brooks; Trevor J Orchard; Graziella E Ronsein; Jay W Heinecke
Journal:  J Clin Endocrinol Metab       Date:  2016-07-11       Impact factor: 5.958

Review 5.  Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment.

Authors:  A N Nafziger
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

Review 6.  Management of lipids in the elderly.

Authors:  A Winder
Journal:  J R Soc Med       Date:  1998-04       Impact factor: 5.344

7.  [Age related decrease of high density lipoproteins (HDL) in women after menopause. Quantification of HDL with genetically determined HDL arylesterase in women with healthy coronary vessels and in women with angiographically verified coronary heart disease].

Authors:  J M Chemnitius; H Winkel; I Meyer; K Schirrmacher; V W Armstrong; H Kreuzer; R Zech
Journal:  Med Klin (Munich)       Date:  1998-03-15

Review 8.  Outcomes of lipid-lowering treatment in postmenopausal women.

Authors:  John C LaRosa
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 9.  Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Authors:  Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams
Journal:  J Midwifery Womens Health       Date:  2008 Jul-Aug       Impact factor: 2.388

10.  Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy.

Authors:  Christos Markopoulos; Urania Dafni; John Misitzis; Vasilios Zobolas; Evagelos Tzoracoleftherakis; Dimitrios Koukouras; Grigorios Xepapadakis; John Papadiamantis; Basileios Venizelos; Zoh Antonopoulou; Helen Gogas
Journal:  Breast Cancer Res       Date:  2009-06-16       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.